The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates
Purpose
Frailty is associated with higher rates of morbidity, mortality, and failure to rescue after major surgical procedures [1]. Sarcopenia is degenerative loss of skeletal muscle mass and strength. It is a key component of physical frailty and is associated with poorer post-surgical outcomes due to decreased patient strength and vitality.
Conditions
- Frailty
- Sarcopenia
- COVID-19
Eligibility
- Eligible Ages
- Between 18 Years and 75 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Age 18 years and older Underwent pre-transplant frailty assessment (PFA) at MDMC
Exclusion Criteria
- Not a patient at Liver Institute at Methodist Dallas
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Recruiting Locations
More Details
- NCT ID
- NCT05935800
- Status
- Active, not recruiting
- Sponsor
- Methodist Health System
Detailed Description
This study seeks to examine whether the SARS-CoV-2 (COVID-19) pandemic, an ongoing global health crisis that was declared a national emergency by the US Federal Government on March 13, 2020, has exacerbated both frailty and sarcopenia in a population of liver transplant candidates.